Core Viewpoint - 康沣生物-B (06922) has entered into a subscription agreement to issue a total of 7.46 million H shares at a subscription price of HKD 5.36 per share, representing a discount of approximately 17.79% compared to the closing price of HKD 6.52 on the Hong Kong Stock Exchange on the same day [1] Group 1: Subscription Details - The subscription agreement is with LP Investment Holdings Group and Mr. Li Jun [1] - The net proceeds from the subscription are approximately HKD 39.73 million [1] Group 2: Use of Proceeds - 80% of the proceeds will be allocated for research, production, and commercialization of minimally invasive interventional products related to vascular intervention, respiratory intervention, and tumor intervention [1] - 20% of the proceeds will be used for general working capital of the group [1]
康沣生物-B拟折让约17.79%发行合共746万股认购股份 净筹约3973万港元